Investigational Drug Information for CORT118335
✉ Email this page to a colleague
What is the development status for investigational drug CORT118335?
CORT118335 is an investigational drug.
There have been 12 clinical trials for CORT118335.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 4th 2020.
The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Weight Gain. The leading clinical trial sponsors are Corcept Therapeutics, National Institute on Alcohol Abuse and Alcoholism (NIAAA), and The Scripps Research Institute.
There are five US patents protecting this investigational drug and sixty international patents.
Summary for CORT118335
| US Patents | 5 |
| International Patents | 60 |
| US Patent Applications | 32 |
| WIPO Patent Applications | 23 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2020-11-04) |
| Vendors | 10 |
Recent Clinical Trials for CORT118335
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | Corcept Therapeutics | Phase 2 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 |
| Phase 1 Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | Corcept Therapeutics | Phase 1 |
Clinical Trial Summary for CORT118335
Top disease conditions for CORT118335
Top clinical trial sponsors for CORT118335
US Patents for CORT118335
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CORT118335 | ⤷ Subscribe | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Subscribe |
| CORT118335 | ⤷ Subscribe | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Subscribe |
| CORT118335 | ⤷ Subscribe | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Subscribe |
| CORT118335 | ⤷ Subscribe | Pyrimidine cyclohexyl glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CORT118335
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CORT118335 | Australia | AU2017210156 | 2036-01-19 | ⤷ Subscribe |
| CORT118335 | Canada | CA3011728 | 2036-01-19 | ⤷ Subscribe |
| CORT118335 | European Patent Office | EP3405101 | 2036-01-19 | ⤷ Subscribe |
| CORT118335 | Spain | ES2861524 | 2036-01-19 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
